Vis enkel innførsel

dc.contributor.authorErsland, Kari Mereteen_US
dc.contributor.authorMyrmel, Lene Secheren_US
dc.contributor.authorFjære, Evenen_US
dc.contributor.authorBerge, Rolf Kristianen_US
dc.contributor.authorMadsen, Liseen_US
dc.contributor.authorSteen, Vidar Martinen_US
dc.contributor.authorSkrede, Siljeen_US
dc.date.accessioned2020-02-07T13:42:00Z
dc.date.available2020-02-07T13:42:00Z
dc.date.issued2019-05
dc.PublishedErsland KM, Myrmel LS, Fjære E, Berge RK, Madsen L, Steen VM, Skrede S. One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects. International Journal of Neuropsychopharmacology. 2019;22(5):358-369eng
dc.identifier.issn1461-1457
dc.identifier.issn1469-5111
dc.identifier.urihttps://hdl.handle.net/1956/21377
dc.description.abstractBackground: Antipsychotic drugs can negatively affect the metabolic status of patients, with olanzapine as one of the most potent drugs. While patients are often medicated for long time periods, experiments in rats typically run for 1 to 12 weeks, showing olanzapine-related weight gain and increased plasma lipid levels, with transcriptional upregulation of lipogenic genes in liver and adipose tissue. It remains unknown whether metabolic status will deteriorate with time. Methods: To examine long-term metabolic effects, we administered intramuscular long-acting injections of olanzapine (100 mg/kg BW) or control substance to female rats for up to 13 months. Results: Exposure to olanzapine long-acting injections led to rapid weight gain, which was sustained throughout the experiment. At 1, 6, and 13 months, plasma lipid levels were measured in separate cohorts of rats, displaying no increase. Hepatic transcription of lipid-related genes was transiently upregulated at 1 month. Glucose and insulin tolerance tests indicated insulin resistance in olanzapine-treated rats after 12 months. Conclusion: Our data show that the continuous increase in body weight in response to long-term olanzapine exposure was accompanied by surprisingly few concomitant changes in plasma lipids and lipogenic gene expression, suggesting that adaptive mechanisms are involved to reduce long-term metabolic adverse effects of this antipsychotic agent in rats.en_US
dc.language.isoengeng
dc.publisherOxford University Presseng
dc.rightsAttribution CC BY-NCeng
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/eng
dc.subjectolanzapineeng
dc.subjectweight gaineng
dc.subjectDiabeteseng
dc.subjectlong-termeng
dc.subjectrateng
dc.titleOne-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effectsen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2019-08-12T09:26:43Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2019 The Author(s)
dc.identifier.doihttps://doi.org/10.1093/ijnp/pyz012
dc.identifier.cristin1709932
dc.source.journalInternational Journal of Neuropsychopharmacology


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY-NC
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY-NC